Department of Biochemistry and Molecular Biology, Stanley S. Scott Cancer Center, LSUHSC School of Medicine, New Orleans, LA, 70112, USA.
Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Mol Cancer. 2018 Jul 16;17(1):100. doi: 10.1186/s12943-018-0851-8.
The disruption of normal gene regulation due to microRNA dysfunction is a common event in cancer pathogenesis. MicroRNA-27b is an example of an oncogenic miRNA, and it is frequently upregulated in breast cancer. MicroRNAs have been found to deregulate tumor metabolism, which typically manifests as heightened cellular glucose uptake in consort with increased flux through glycolysis, followed by the preferential conversion of glycolytic pyruvate into lactate (a phenomenon known as the Warburg Effect). Pyruvate Dehydrogenase, an enzyme complex linking glycolysis with downstream oxidative metabolism, represents a key location where regulation of metabolism occurs; PDHX is a key structural component of this complex and is essential for its function.
We sought to characterize the role of miR-27b in breast cancer by identifying novel transcripts under its control. We began by utilizing luciferase, RNA, and protein assays to establish PDHX as a novel target of miR-27b. We then tested whether miR-27b could alter metabolism using several metabolite assay kits and performed a seahorse analysis. We also examined how the altered metabolism might affect cell proliferation. Lastly, we confirmed the relevance of our findings in human breast tumor samples.
Our data indicate that Pyruvate Dehydrogenase Protein X is a credible target of miR-27b in breast cancer. Mechanistically, by suppressing PDHX, miR-27b altered levels of pyruvate, lactate and citrate, as well as reducing mitochondrial oxidation and promoting extracellular acidification. These changes corresponded with an increased capacity for cell proliferation. In human breast tumor samples, PDHX expression was deficient, and low levels of PDHX were associated with reduced patient survival.
MicroRNA-27b targets PDHX, resulting in an altered metabolic configuration that is better suited to fuel biosynthetic processes and cell proliferation, thereby promoting breast cancer progression.
由于 microRNA 功能障碍导致正常基因调控的中断是癌症发病机制中的常见事件。microRNA-27b 是一种致癌 microRNA,在乳腺癌中经常上调。microRNAs 已被发现可使肿瘤代谢失调,通常表现为细胞葡萄糖摄取增加,同时糖酵解通量增加,随后将糖酵解丙酮酸优先转化为乳酸(称为瓦伯格效应)。丙酮酸脱氢酶(一种将糖酵解与下游氧化代谢联系起来的酶复合物)是代谢调节的关键部位;PDHX 是该复合物的关键结构组成部分,对于其功能至关重要。
我们试图通过鉴定受其调控的新型转录本来确定 miR-27b 在乳腺癌中的作用。我们首先利用荧光素酶、RNA 和蛋白质测定来确定 PDHX 是 miR-27b 的一个新靶点。然后,我们使用几种代谢物测定试剂盒测试了 miR-27b 是否可以改变代谢,并进行了 Seahorse 分析。我们还研究了改变的代谢可能如何影响细胞增殖。最后,我们在人类乳腺癌肿瘤样本中证实了我们发现的相关性。
我们的数据表明,丙酮酸脱氢酶蛋白 X 是乳腺癌中 miR-27b 的一个可信靶点。从机制上讲,通过抑制 PDHX,miR-27b 改变了丙酮酸、乳酸和柠檬酸的水平,同时减少了线粒体氧化并促进了细胞外酸化。这些变化与细胞增殖能力的提高相对应。在人类乳腺癌肿瘤样本中,PDHX 表达缺失,低水平的 PDHX 与患者生存率降低相关。
microRNA-27b 靶向 PDHX,导致代谢构型改变,更适合为生物合成过程和细胞增殖提供燃料,从而促进乳腺癌进展。